![[Novel migraine treatment with CGRP-related monoclonal antibodies] - PubMed](https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png "[Novel migraine treatment with CGRP-related monoclonal antibodies] - PubMed")
Aimovig®: One dose, once a month, designed to work 24/7 all month long to help prevent migraine in adults
In a usability study of the SureClick® autoinjector among adult migraine patients (N = 204):
- 96% found the autoinjector easy to use2,†
- 93% would recommend the autoinjector to other patients2,†
Aimovig® is an anti-CGRP therapy that includes one monthly dose designed to work all month long to help prevent migraine.
Click here for resources to help your Aimovig patients, including those you have started through telemedicine.
†204 autoinjector-naïve adult migraine patients were evaluated in a usability study of the Aimovig SureClick® single-dose autoinjector by performing a simulated injection. Percentages were derived from a combination of patients who stated that they completely agree or somewhat agree on a 5-point Likert scale.2
INDICATION
Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.
Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.
Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.
Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.
Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.
Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.
Please see accompanying Aimovig® full Prescribing Information
References: 1. Aimovig® (erenumab-aooe) Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2020. 2. Mead J, et al. Patient Reported Ease of Use with Disposable Autoinjector in Individuals with Migraine. Patient Preference and Adherence. 2020:14 1137-1144.
© 2020 Amgen Inc. All rights reserved. USA-334-84118 09/20
